WuXi AppTec : REPLY SLIP FOR THE THIRD H SHARE CLASS MEETING FOR 2019 TO BE HELD ON MONDAY, NOVEMBER 18, 2019
October 04, 2019 at 04:47 am EDT
Share
WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)
REPLY SLIP FOR THE THIRD H SHARE CLASS MEETING FOR 2019
TO BE HELD ON MONDAY, NOVEMBER 18, 2019
To: WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the "Company")
I/We (Note 1)
of
being the registered holder(s) of (Note 2)H shares of RMB$1.00
each in the share capital of the Company hereby inform the Company that I/we intend to attend or appoint proxy to attend on my/our behalf the third H Share class meeting of the Company for 2019 to be held at 2:00 p.m. at Building No. 18, Lane 31, Yiwei Road, Pudong New Area, Shanghai, the PRC on Monday, November 18, 2019.
Date:
2019
Signature(s):
Notes:
Please insert the full name(s) and address(es) (as shown in the register of members) in BLOCK CAPITALS.
Please insert the number of shares registered in your name(s). If no number is inserted, this reply slip will be deemed to relate to all shares registered in your name(s).
Please complete and sign this reply slip and return it to the Company's H Share Registrar, Tricor Investor Services Limited on or before Tuesday, October 29, 2019 by hand, by post or by fax.
The address and contact details of the Company's H Share Registrar, Tricor Investor Services Limited, are as follows:
Level 54, Hopewell Centre 183 Queen's Road East Hong Kong
Telephone No.: (852) 2980 1333
Facsimile No.: (852) 2810 8185
for identification purposes only
Attachments
Original document
Permalink
Disclaimer
WuXi AppTec Co. Ltd. published this content on 04 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 October 2019 08:46:14 UTC
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:
- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;
- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;
- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;
- other (0.1%).
Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
WUXI APPTEC CO., LTD. 
